TEAMS

Ian HUDSON started his career with ICI, a former UK based multinational in chemicals and related sectors. In 1998, he joined DuPont de Nemours and held during a period of 17 years, several leading positions within the Company. He retired from the company in 2016 after serving 10 years as  President Europe Middle East & Africa. He served as  a member of the Executive Committee and Board of CEFIC and of EuropaBio. He was also a  member of the Foundation Board of IMD and a member of the Swiss-American Chamber of Commerce. Mr HUDSON graduated from Oxford University with an MA degree in French and German.

Co-founder and General Director of Truffle Capital, one of the leading venture capital company in Europe, Philippe Pouletty is a Biotech and Medtech industry veteran with dual experience in Silicon Valley and in France.

Philippe Pouletty is Co-Founder et Board member of Carmat (Euronext Growth: ALCAR), Founder and President of Deinove (Euronext Growth: ALDEI), and Abivax (Euronext: ABVX), Founder of Carbios (Euronext Growth: ALCRB), Co-Founder et Board member of Pharnext (Euronext Growth: ALPHA) and Vexim (sold to Striker Corporation 183m euros in 2017), Président of Diaccurate, Board member of Myopowers, Biokinesis, Kephalios, all part of Truffle Capital’s portfolio. MD from the University of Paris VI, hematology and immunology resident in Paris hospital, MS degrees in immunology (with honours) and virology from Pasteur Institute, he was a post-doctoral research fellow (1986-1988) at Stanford University and became laureate of the American Liver Foundation in 1999. Philippe Pouletty is Honorary President and founder of France Biotech (French association of biotechnology) and former Vice-President of the European Association for the biotechnology industry EuropaBio. He is also the inventor of the Young Innovative Entreprise Status (JEI), implemented by President Chirac in 2004 in France, and recently named as the best tax incentive by the European Commission. Philippe POULETTY is the author of 29 patents, including one that generates the second most important income for Stanford University in life sciences. In 2012, he entered the prestigious Stanford University Hall of Fame of Inventors.

Jean Falgoux has had a 40-year career in three life sciences companies. At the Japanese group Ajinomoto, the world leader in biochemically-produced amino acids, Mr. Falgoux was CEO, then President of Ajinomoto Eurolysine, Vice President of Ajinomoto Europe and Corporate Executive Officer of Ajinomoto Inc. He also served as an Executive Committee member of several of Ajinomoto’s European affiliates. At the pharmaceutical group Roussel Uclaf, Mr. Falgoux began in a marketing role, going on to become Director of business development at the company’s US-based agro-veterinary affiliate and later leading the global animal health unit. He then joined the Hoechst Roussel group in Germany where he was Senior Vice President and then Geschäftführer (Managing Director) at Hoechst Roussel Vet GmbH. His career began in research and development at Rousselot, a leading European gelatine producer. Mr. Falgoux is an active Board member in several other companies.

Dr. Jacqueline Lecourtier is an engineer and graduate of the ENSIC (Chemical Engineering School in Nancy) with a doctorate in physics, She held various positions at the IFP, including Drilling Production Director, then Scientific Director. Dr. Lecourtier was also Managing Director of the French National Research Agency (ANR). She is currently President of the Scientific Councils of the IFREMER (French Research Institute for Exploitation of the Sea), and PRINCIPIA. She is also President of the Strategic Policy and Foresight Committee of the Université Paris VI, and a member of the Boards of Directors of the ENS (Ecole Normale Supérieure) Lyon, Mines ParisTech (Ecole des Mines de Paris), and the ENCL.

Following his first work experience in South Korea, Pascal Juery began his career as an internal auditor at Rhône-Poulenc in 1998. He went on to hold various management positions within the Rhodia group’s Novecare unit, first as Director of European Operations, then as Director of the Home & Personal Care Division, Worldwide. In 2006, he was appointed Sales Director of Rhodia.  In 2008, he relocated to the United States to lead Rhodia Novecare as its Managing Director before joining Rhodia’s executive committee in 2010. After the group’s merger with Solvay in 2011, he became Chairman of Solvay Essential Chemicals. Mr. Juery joined the executive committee of Solvay in January 2014. He is a graduate of ESCP Europe.

Mr. Jacques Breuil joined the Group Barbier in 1987 where he held the position of General Secretary. Mr. Breuil is also board member of the Industrial Technical Centre of Plasturgy and Composites (CTIPC) since February 2016, member of the executive Council of Céreales Vallée (A competitive cluster of the cereals industry) since 2015 and board member of Plastipolis (A competitive cluster of the plastic industry) since May 2015. He was previously Chief Financial Officer of a food-processing company (with 100 M€ annual turnover) and founder of an IT services company sold to Sema Group, (today ATOS) in 1986. Jacques Breuil holds a Master of Economy (from the Conservatoire National des Arts et Métiers – CNAM) and an Executive MBA (ICG/IFG/SORBONNE)

Godefroy MOTTE joined Eastman Chemical Company in 1985, where he held during more than 30 years several leading positions before becoming Board member in 2011. He gained his experience in a cross-functional career (Sales, Marketing, Business, Manufacturing, General Management), working and living in 5 different countries. Relevant to CARBIOS, he was the Operations Manager for the efficient start-up of a greenfield PET plant (120KMT) in San Roque, Spain and the VP, EMEA Operations, for 17 manufacturing sites. Passionate about Specialty Chemicals, Biotech and Renewable Chemistry, M. MOTTE created, in 2016, his advisory boutique “Adrialis” to help innovative companies optimize their business portfolio, as well as creating value-added partnerships with strategic and financial investors. Mr. MOTTE graduated from the “école des Hautes Etudes Industrielles” with a Chemical Engineer degree and from the Advanced Management Program at Harvard University (2008).

Alain Chevallier is Partner Life Sciences at Truffle Capital. He devoted the first thirty years of his professional career to important pharmaceutical groups such as Aventis Pharma, where he was a member of the Executive Board in charge of finance; Sanofi-Aventis, where he served as Financial Director in France; and Abivax, where he served as Financial Director until January 2017. Since 2007, Mr. Chevallier has held positions that include as counselor, administrator and director, assisting young innovative companies with their development strategy. One of these, Deinove benefitted from his input when it was listed on the Alternext market of Euronext Paris in 2010. Until December 2016, he was CFO of Abivax and President of Deinobiotics. Mr. Chevallier is a graduate of the HEC Master of Business Administration program.